AMBALALSA · Ambalal Sarabhai Enterprises Ltd · Major Drugs
AMBALALSA · Ambalal Sarabhai Enterprises Ltd · Major Drugs
As of 05 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹44 Cr
Revenue YoY
PAT YoY
-51.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.3
P/S (TTM)
1.5
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| AMBALALSA (this stock) | 18.5 | 2.3 | +6.6% | +8.6% | 0.4 | 0.0% |
| Aurobindo Pharma | 24.7 | 2.9 | +10.6% | +9.8% | 0.21 | 0.0% |
| Neuland Laboratories | 64.3 | 12.6 | +18.0% | +21.4% | 13.9 | +0.2% |
| Pfizer | 27.6 | 5.1 | +28.6% | +17.5% | 0.02 | +1.9% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in AMBALALSA's filed documents yet.